{"id":457648,"date":"2019-12-18T13:26:01","date_gmt":"2019-12-18T13:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=457648"},"modified":"2019-12-18T13:26:01","modified_gmt":"2019-12-18T13:26:01","slug":"cough-and-cold-drugs-market-to-grow-at-a-cagr-of-35-during-20182022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cough-and-cold-drugs-market-to-grow-at-a-cagr-of-35-during-20182022_457648.html","title":{"rendered":"Cough and Cold Drugs Market To Grow At A CAGR Of 3.5% During 2018-2022"},"content":{"rendered":"
\"Cough<\/a><\/p>\n
\n
Global Cough And Cold Drugs Market Report 2019\n<\/div>\n<\/div>\n<\/div>\n
AstraZeneca Is One Of The Largest Companies In The Cough And Cold Preparations Market, According To TBRC\u2019s Report
\n(Companies: AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline)\n<\/div>\n

Take a look at our year-end deals on Opportunities and Strategies Reports! Up to 50% off on all licenses.<\/em><\/strong><\/p>\n

https:\/\/www.thebusinessresearchcompany.com\/discounted-reports.aspx<\/a><\/p>\n

The global cough and cold preparations market was valued at about $23.2 billion in 2018 and is expected to grow to $26.61 billion at a CAGR of 3.5% through 2022. Major players in the market are AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline. <\/p>\n

The cold and cough preparations market consists of sales of drugs for cold and cough. The drugs for the treatment of cold and cough acts on the receptors to which the virus causing the infection gets attached to, by antagonizing the action of the receptors and killing the viral infection, thereby reducing congestion by lysing the mucus and dilating the bronchioles constricted by the mucus deposition. In this market, sales of antihistamines, antibiotics, decongestants, expectorants and bronchodilators are also included.<\/p>\n

View more @<\/strong> https:\/\/www.thebusinessresearchcompany.com\/report\/cough-and-cold-preparations-global-market-report<\/a><\/p>\n

The cold and flu season is the major driver of sales for products related to prevention and treatment of cold and cough. Cold weather is not directly associated with common cold, but the virus which causes common cold, called rhinovirus, is responsible for all cold related illnesses. Once the virus is inhaled, it attaches to the cells in nasal passages. According to a research study, rhinoviruses replicates more efficiently at temperatures lower than 37°C, or 98.6°F, which is the average core body temperature in humans. The temperature inside the nasal cavity is approximately 33°C (91.4°F), which may make it an ideal breeding ground for rhinoviruses. Although flu viruses are generally present year-round, they are most common during the fall and winter seasons. Therefore, sales of vaccines and other drug products that help alleviate the symptoms of colds and cough, and products which help the body naturally prevent and treat cold and flu symptoms is driving the market for cold and cough drugs.<\/p>\n

Request a Sample Copy of Report @<\/strong> https:\/\/www.thebusinessresearchcompany.com\/sample.aspx?id=2585&type=smp<\/a><\/p>\n

Few Points From Table Of Contents:<\/strong><\/p>\n

1. Executive Summary<\/p>\n

2. Cold and Cough Preparations Market Characteristics<\/p>\n

3. Cold and Cough Preparations Market Size And Growth<\/p>\n

3.1. Global Cold and Cough Preparations Historic Market, 2014 – 2018, $ Billion<\/p>\n

3.1.1. Drivers Of The Market<\/p>\n

3.1.2. Restraints On The Market<\/p>\n

3.2. Global Cold and Cough Preparations Forecast Market, 2018 – 2022F, 2025F, 2030F, $ Billion<\/p>\n

3.2.1. Drivers Of The Market<\/p>\n

3.2.2. Restraints On the Market<\/p>\n

4. Cold and Cough Preparations Market Segmentation<\/p>\n

4.1. Global Cold and Cough Preparations Market, Segmentation By Drug Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion<\/p>\n

Antihistamines<\/p>\n

Expectorants<\/p>\n

Bronchodilators<\/p>\n

Decongestants<\/p>\n

Antibiotics<\/p>\n

Others<\/p>\n

4.2. Global Cold and Cough Preparations Market, Segmentation By Dosage Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion<\/p>\n

Oral Syrups<\/p>\n

Tablets\/Pills<\/p>\n

Nasal Drops<\/p>\n

Lozenges<\/p>\n

Others<\/p>\n

4.3. Global Cold and Cough Preparations Market, Segmentation By Distribution Channel, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion<\/p>\n

Hospital Pharmacies<\/p>\n

Retail Pharmacies<\/p>\n

Drug Stores<\/p>\n

5. Cold and Cough Preparations Market Regional And Country Analysis<\/p>\n

Place a Direct Purchase Order Of Entire Report @<\/strong> https:\/\/www.thebusinessresearchcompany.com\/purchaseoptions.aspx?id=2585<\/a> <\/strong><\/p>\n

About The Business Research Company<\/strong><\/p>\n

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 20 countries globally.<\/p>\n

Contact Information<\/p>\n

The Business Research Company<\/p>\n

Europe: +44 207 1930 708<\/p>\n

Asia: +91 8897263534<\/p>\n

Americas: +1 315 623 0293<\/p>\n

Email: info@tbrc.info<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Business Research Company<\/a>
Contact Person:<\/strong> Nitin
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 08897263534
Address:<\/strong>1st Floor, Anshu Colors Building, Road Number 1 Park View Enclave, Jubilee Hills
City:<\/strong> Hyderabad 500033
State:<\/strong> Telengana
Country:<\/strong> India
Website:<\/strong> https:\/\/www.thebusinessresearchcompany.com\/report\/cough-and-cold-preparations-global-market-report<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Global Cough And Cold Drugs Market Report 2019 AstraZeneca Is One Of The Largest Companies In The Cough And Cold Preparations Market, According To TBRC\u2019s Report (Companies: AstraZeneca, Bayer, Blackmores Limited, Dabur, GlaxoSmithKline) Take a look at our year-end deals … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,424,405,406,404],"tags":[],"class_list":["post-457648","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Family-Parenting","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=457648"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/457648\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=457648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=457648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=457648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}